IPP Bureau
Biocon Biologics honored as 2025 Asia IP Elite by IAM for 9th consecutive year
By IPP Bureau - December 18, 2025
This recognition demonstrate excellence in intellectual property (IP) value creation.
AstraZeneca India receives permission from CDSCO for Datopotamab Deruxtecan powder
By IPP Bureau - December 18, 2025
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
Godavari Biorefineries launches US biotech arm to advance novel cancer therapies
By IPP Bureau - December 18, 2025
The move strengthens GBL’s clinical-stage presence in the United States
Merck’s KEYTRUDA–Padcev combo delivers survival gains in Phase 3 bladder cancer trial
By IPP Bureau - December 18, 2025
Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer
By IPP Bureau - December 18, 2025
The combination also outperformed chemotherapy on another important secondary endpoint
FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer
By IPP Bureau - December 18, 2025
Patients with BRCA mutations often face aggressive disease and poor prognosis
Eli Lilly re-elects Nobel Laureate Carolyn Bertozzi to Board
By IPP Bureau - December 17, 2025
Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute
Lupin secures SBTi validation for emission reduction targets
By IPP Bureau - December 17, 2025
Glenmark secures exclusive multi-regional rights to Aumolertinib from Hansoh Pharma
By IPP Bureau - December 17, 2025
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Remedium Lifecare is now Supha Pharmachem
By IPP Bureau - December 17, 2025
The company shall process the change of name application with BSE Ltd. in due course
Lupin receives EIR from USFDA for Nagpur injectable facility
By IPP Bureau - December 17, 2025
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
AstraZeneca wins EU nod for self-administered lupus drug Saphnelo
By IPP Bureau - December 17, 2025
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Cynata completes patient enrollment for Phase 2 aGvHD clinical trial
By IPP Bureau - December 17, 2025
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
Bristol Myers Squibb launches AI-powered ‘Mosaic’ hub in Mumbai
By IPP Bureau - December 17, 2025
India plays a critical role in Bristol Myers Squibb’s global strategy
Revvity unveils AI-powered Signals Xynthetica to accelerate molecular and materials design
By IPP Bureau - December 17, 2025
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
